Menarini
Menarini is an Italian privately owned pharmaceutical and healthcare group headquartered in Florence.
Last updated August 25, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Menarini is an Italian pharmaceutical and healthcare group whose history began in 1886 at the Farmacia Internazionale in Naples. Founded by Doctor Archimede Menarini, the business initially combined conventional pharmacy activity with the preparation and distribution of galenic medicines. Early products sold under the Menarini name included Metarsile, an iron-based restorative that remained in production into the twentieth century, and Euzymina, a digestive preparation. The company moved its operations from Naples to Florence in 1915, establishing the city that remains its corporate home. Over the following decades, Menarini developed through a combination of internal research, manufacturing expansion, international subsidiaries, and acquisitions. Its portfolio broadened beyond traditional pharmaceutical preparations into medicines for cardiovascular disease, pain and inflammation, respiratory conditions, infectious diseases, and oncology. The group also built specialized capabilities in diagnostics and biotechnology. Menarini Diagnostics became an important division, supplying glucose self-monitoring systems, laboratory reagents, and instruments serving areas such as haematology, clinical chemistry, urinalysis, and immunology. The group’s expansion accelerated from the 1960s onward. It acquired the Spanish laboratory Puig Sala, which became Laboratorios Menarini, and subsequently purchased established Italian pharmaceutical businesses including Malesci, Guidotti, Lusofarmaco, and FIRMA. The addition of Berlin Chemie in 1992 gave Menarini a substantial presence in Germany and Central and Eastern Europe. Further international development included operations in Central America and the Caribbean, India, Turkey, Argentina, Mexico, and the Asia-Pacific region. The company also invested in manufacturing sites and research facilities in Italy, Spain, Germany, Ireland, Turkey, Indonesia, Russia, and Guatemala. Menarini organizes much of its scientific activity through three principal areas: Menarini Ricerche, Menarini Biotech, and Menarini Diagnostics. Menarini Ricerche covers the drug-development process from project creation and preclinical work through registration. Menarini Biotech supports the development and production of biotechnology medicines, while Menarini Diagnostics focuses on diabetes monitoring and laboratory diagnostics. The group has also developed specialist capabilities in biomarkers and precision medicine, including rare-cell analysis and single-cell research through Menarini Silicon Biosystems. In 2020, Menarini acquired Stemline Therapeutics, a United States biopharmaceutical company focused on oncology. The transaction strengthened the group’s presence in cancer medicines and added an international development platform. Menarini also developed a rapid COVID-19 diagnostic test during the pandemic, reported as providing results in approximately twenty minutes. By 2025, the group reported operations through subsidiaries and distributors in 140 countries, approximately 17,800 employees, and 18 manufacturing plants. Its activities included pharmaceutical research, production, commercialization, biotechnology, oncology, and diagnostics. Menarini remains privately controlled by the Aleotti family. Massimiliana Landini Aleotti and her children inherited the business after the death of Alberto Aleotti in 2014. The group is not publicly traded and does not have a stock-market ticker. In addition to commercial operations, Menarini has supported medical education, social housing renovation in Florence, child-abuse prevention initiatives, and the Fair Play Menarini International Award. The company has also attracted criticism for continuing operations in Russia after the invasion of Ukraine and the introduction of related international sanctions.
History
Menarini traces its origins to 1886, when Doctor Archimede Menarini established the Farmacia Internazionale in Naples. The early business manufactured and distributed galenic preparations alongside normal pharmacy operations. Among the first medicines marketed under the Menarini name were Metarsile, an iron phospho-methylarsenate restorative, and Euzymina, a digestive preparation containing digestive ferments and lecithin. In 1915, the company transferred its operations to Florence, partly because the city was close to important glassmaking facilities needed for pharmaceutical packaging. The company gradually transformed from a local pharmacy laboratory into a broader pharmaceutical group. In the 1960s it acquired the Spanish laboratory Puig Sala, founded in Barcelona in 1924. The Spanish operation later became Laboratorios Menarini. Its facilities moved to Badalona in 1972, where the business expanded its manufacturing footprint and focused on medicines for cardiovascular conditions, inflammation, and pain, as well as operations in Central America and the Caribbean. Menarini began building specialized healthcare divisions during the 1970s. Menarini Diagnostics was established in 1976, initially as an Italian distributor of laboratory systems. It later added a technology department, quality-control laboratory, and manufacturing capability. Diabetes self-monitoring systems became part of its offering from the 1980s. The Fondazione Internazionale Menarini was also created in 1976 to promote scientific and cultural exchange in biology, pharmacology, medicine, economics, and the humanities, including international congresses. In 1978, Menarini acquired Malesci, a Florentine pharmaceutical company with roots dating to 1850. Internationalization continued in the 1980s and 1990s. A Central American and Caribbean affiliate was established in 1982, with headquarters and manufacturing in Guatemala. Between 1983 and 1984, Menarini acquired Guidotti of Pisa, Lusofarmaco of Milan, and FIRMA. The group founded a research toxicology center in Pomezia in 1987 and developed additional research infrastructure, including the Menarini Research Campus in 1992. Berlin Chemie joined the group in 1992, substantially broadening its reach in Germany and Central and Eastern Europe. Menarini also established a French subsidiary in the same year. The company expanded its production and biotechnology capabilities through the 1990s and 2000s. A plant in L'Aquila opened in 1993. Menarini entered India through a partnership in 1994 and created an over-the-counter division that year. It later acquired the Turkish laboratory IE Ulagay in 2001 and established an Argentine affiliate. A biotechnology production plant in Pomezia was established in 2003, building on biotechnology work conducted in Italy since the 1980s. The Menarini-von Heyden manufacturing facility in Dresden was inaugurated in 2006, followed by a Mexican affiliate in 2008. In 2011, Menarini acquired Invida, turning it into Menarini Asia-Pacific and strengthening the group’s presence across Asian markets. In 2013, it acquired Silicon Biosystems, an Italian company specializing in rare-cell research and single-cell analysis. The business became Menarini Silicon Biosystems and later incorporated activities associated with the CellSearch system. Menarini Biomarkers was established in 2014 to work on biomarkers, including applications in prenatal diagnosis and lung and ocular cancers. The group also opened a pharmaceutical manufacturing site in Kaluga, Russia, during the same year. Ownership passed to Massimiliana Landini Aleotti and her three children following the death of her husband in May 2014. Governance began to change in 2018, when Eric Cornut became the first chairman recruited from outside the owning family. In September 2019, the board appointed Elcin Barker Ergun as chief executive officer. The COVID-19 pandemic prompted Menarini to develop a rapid diagnostic test in 2020. That year the group also acquired Stemline Therapeutics, a United States oncology biopharmaceutical company. The transaction reinforced Menarini’s strategic focus on cancer medicines and provided an international platform for oncology development and commercialization. By 2025, Menarini reported 17,800 employees, 18 manufacturing plants, distribution through subsidiaries and partners in 140 countries, and three principal operating divisions: Menarini Ricerche, Menarini Biotech, and Menarini Diagnostics. The group also reported producing 609 million units in 2024 and continued to operate as a privately controlled pharmaceutical business. Its international footprint has nevertheless generated criticism, particularly concerning continued operations in Russia after the introduction of sanctions related to the war in Ukraine.
- 2025
Global group reports 17,800 employees
[1]Menarini reported 17,800 employees and operations through subsidiaries and distributors in 140 countries.
- 2020
Stemline Therapeutics acquired
[1]Menarini entered a major oncology expansion through the acquisition of Stemline Therapeutics.
- 2019
Elcin Barker Ergun becomes CEO
[1]The board appointed Elcin Barker Ergun as chief executive officer.
- 2018
First external chairman appointed
[1]Eric Cornut became the first chairman from outside the owning family.
- 2014
Menarini Biomarkers established
[1]The group created a biomarkers business focused on applications including prenatal diagnosis and cancer research.
- 2013
Silicon Biosystems acquired
[1]Menarini acquired the Italian rare-cell research company, later operated as Menarini Silicon Biosystems.
- 2011
Invida acquired
[1]The acquisition created Menarini Asia-Pacific and expanded the group's regional network.
- 2003
Biotechnology production plant established
[1]Menarini opened a biotechnology production facility in Pomezia, Italy.
- 1992
Berlin Chemie joins the group
[1]The acquisition of Berlin Chemie expanded Menarini's presence in Germany and Central and Eastern Europe.
- 1982
Central American affiliate established
[1]The group opened its first affiliate in Central America and the Caribbean, based in Guatemala.
Products and positioning
A privately controlled, research-led international pharmaceutical and healthcare group combining prescription and consumer medicines with biotechnology, oncology, and diagnostics.
Historical pharmaceutical · 1886
Metarsile
Metarsile was one of the earliest medicines distributed under the Menarini name. It was described as a restorative based on iron phospho-methylarsenate and remained in production until the 1960s. It represents the company’s early transition from pharmacy-based galenic preparation toward branded pharmaceutical products.
Historical digestive medicine · 1886
Euzymina
Euzymina was an early Menarini-branded preparation containing digestive ferments and lecithin. It was marketed for digestive disorders and formed part of the company’s first generation of branded medicines produced from its Naples pharmacy origins.
Prescription medicines
Prescription pharmaceutical portfolio
Menarini develops and commercializes prescription medicines across several therapeutic areas, including cardiovascular disease, oncology, pain and inflammation, asthma and other respiratory conditions, and infectious diseases. The portfolio is supported by research, regulatory, manufacturing, and international commercialization capabilities across the group.
Medical diagnostics · 1976
Menarini Diagnostics
Menarini Diagnostics supplies glucose self-monitoring systems, laboratory reagents, and diagnostic technologies. Its stated areas include diabetes, haematology, clinical chemistry, urinalysis, and immunology. The division operates through an international network of affiliates, partners, and distributors.
Biotechnology medicines · 1986
Menarini Biotech
Menarini Biotech supports biotechnology medicines from early research through pilot-scale development and industrial production. Its activities complement the group’s conventional pharmaceutical research and manufacturing infrastructure.
Precision diagnostics and research technology · 2013
Menarini Silicon Biosystems
Menarini Silicon Biosystems develops technologies for rare-cell research and single-cell analysis. The business became part of Menarini after the acquisition of Silicon Biosystems in 2013 and subsequently incorporated corporate activities related to the CellSearch system.
Oncology medicines · 2020
Menarini Stemline oncology portfolio
Menarini Stemline is the group's oncology-focused business following the 2020 acquisition of Stemline Therapeutics. It provides an international platform for the development and commercialization of cancer therapies. By 2025, the business was reported to have obtained approvals from major regulatory authorities worldwide for three oncology drugs.
COVID-19 diagnostic test · 2020
Rapid COVID-19 test
Menarini developed a rapid COVID-19 diagnostic test during the pandemic in Italy. The test was reported as capable of producing a result in approximately twenty minutes, supporting the group’s expansion of diagnostic activity during the public-health emergency.
Controversies
Criticism over continued Russian operations
Menarini faced criticism from organizations concerned with corporate accountability and ethical conduct because it continued operating in Russia after international sanctions were imposed in connection with Russia’s invasion of Ukraine. The available material does not establish a formal legal finding or quantify the commercial impact.
Marketing campaigns
- 2016Paediatric network against ill-treatment of minors
Italy · Balkans · Europe
Menarini supported a child-abuse prevention network with Telefono Azzurro, the Italian Federation of Paediatricians, and the Association of Italian Paediatric Hospitals. The initiative trained paediatricians and general practitioners to recognize warning signs of abuse and act as local referral points.
Outcome. The project was launched in Florence in May 2016 and later presented in Tirana to paediatricians from the Balkans and other European countries. The reference material describes a planned Italian network of approximately 15,000 paediatricians and general practitioners.
- 2013Florence social housing renovation project
Florence, Italy
Menarini partnered with the Municipality of Florence to renovate publicly owned social-housing apartments and make them available to families identified through the city’s social-housing process.
Outcome. The project delivered multiple rounds of renovated apartments between 2014 and 2016. The reference material reports that twenty apartments were ultimately recovered and assigned to families.
- 2011Fair Play Menarini International Award
International
Menarini became title sponsor of the Fair Play Menarini International Award, which recognizes conduct by athletes and sports figures associated with loyalty, fairness, respect for rules, and sporting values.
Outcome. Since 2021, the award has been organized independently by the Fair Play Menarini Foundation, with recipients serving as ambassadors for the award’s fair-play message.
Brand decisions
2020
Acquire Stemline TherapeuticsM&ABackground
Menarini wanted to strengthen its oncology pipeline and gain a larger position in the United States biopharmaceutical market.
Action taken
Menarini acquired Stemline Therapeutics, a Nasdaq-listed U.S. biopharmaceutical company focused on oncology therapies.
Aftermath
Stemline became the foundation of Menarini’s expanded oncology platform. By 2025, Menarini Stemline was reported to have received approvals for three oncology drugs from major regulatory authorities worldwide.
2020
Develop rapid COVID-19 diagnostic testProduct launchBackground
The COVID-19 pandemic created demand for faster diagnostic testing in Italy and internationally.
Action taken
Menarini developed a rapid COVID-19 test reported to provide results in approximately twenty minutes.
Aftermath
The development highlighted Menarini’s diagnostics capabilities during the pandemic, although the available material does not provide detailed sales or regulatory data.
2013
Acquire Silicon BiosystemsM&ABackground
Menarini was broadening from conventional pharmaceuticals into specialized diagnostics and precision biomedical research.
Action taken
The group acquired Italian start-up Silicon Biosystems, which specialized in rare-cell research and single-cell analysis.
Aftermath
The business became Menarini Silicon Biosystems and expanded the group’s capabilities in rare-cell technologies and CellSearch-related activities.
2011
Acquire InvidaM&ABackground
Menarini aimed to build a broader presence in Asian pharmaceutical markets.
Action taken
The group acquired Invida and converted the business into Menarini Asia-Pacific.
Aftermath
The transaction expanded Menarini’s regional network across South Asian and Asia-Pacific markets.
1992
Acquire Berlin ChemieM&ABackground
Menarini sought to expand its European pharmaceutical presence and enter or strengthen access to Central and Eastern European markets.
Action taken
The group acquired Berlin Chemie, a German pharmaceutical company founded in 1890.
Aftermath
Berlin Chemie became a major platform for Menarini’s activities in Germany and Central and Eastern Europe.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/menarini · Editorial policy · How profiles are compiled